Clinical trial NCT02777905: Mindfulness-Based Cognitive Therapy for Depression and Anxiety
Official title: Group Mindfulness-Based Cognitive Therapy for the Treatment of Late-Life Depression and Anxiety Symptoms in Primary Care: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Symptoms of Depression
Symptoms of Anxiety
Keywords: late life
mindfulness meditation
Lead sponsor: Lady Davis Institute
Sponsor class: OTHER
First posted: 2016-05-19
Enrollment: 100
Sex: ALL
Minimum age (years): 60
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: About 10-20% of older patients in primary care suffer from symptoms of depression and/or anxiety. Depression and anxiety are associated with higher rates of cognitive decline, lower quality of life, increased medical comorbidity, and higher mortality rates in these patients. Given the world's aging population and consequent rapid increase in older patients in primary care, many traditional therapeutic approaches for depression or anxiety in this patient population - e.g. assessment by a mental health practitioner, individual psychotherapy and/or appropriate psychotropic medication - have been inadequate, with many patients having undetected depression and anxiety. Additionally, geriatric depression and anxiety are very common, but difficult to treat with psychotropic medications: patients are more sensitive to adverse effects and respond relatively less well to medication.

To help with this issue, the investigators are conducting a randomized controlled trial of mindfulness-based cognitive therapy (MBCT), a treatment that has been highly effective in treating depression and anxiety, but has not yet been assessed in older adults. There has been relatively little information about MBCT's effectiveness, particularly in the primary care setting and in the acute treatment of depression and anxiety(vs. maintenance treatment).

This study will be conducted in 75-100 older adults in primary care with symptoms of anxiety and depression. The study will take place in the "centre local de services communautaires" CLSC Benny Farm, a primary health care centre in Montreal, Canada. Most patients aged 60+ with symptoms of depression (Patient Health Questionnaire 9 (PHQ-9) score ≥10) or anxiety (General Anxiety Disorder-7 (GAD- 7) score ≥10) will be eligible. Patients who are eligible for the study will be randomized: half the patients will get 8-week MBCT with a trained interventionist (occupational therapist, psychiatry resident, or psychiatrist). The other half (control group) will get patient treatment as usual with patient primary care physician/primary care team during the study, but then after the study, patients will be offered the treatment if patients would like.


Eligibility criteria: Inclusion Criteria:

* Patients at least 60 years of age and above (clinical experience shows, that almost all patients with depressive and anxiety symptoms aged 60+ are able to participate in group MBCT)
* Patients with depression and/or anxiety symptoms as indicated by scores of ≥10 on the Patient Health Questionnaire (PHQ-9) and/or General Anxiety Disorder-7 (GAD- 7)
* Normal cognition or Mild Cognitive Impairment ("Normal" Result on the 3-minute Mini-Cog Test) \[28\]

Exclusion Criteria:

* Mild, Moderate, or Severe Dementia ("Abnormal" Result on the 3-minute Mini-Cog Test)
* Acute psychotic symptoms
* Severe personality problems that will interfere with their ability to function in a group setting
* Acute Suicidal ideation/intent
* Change in psychotropic medication during the 8 weeks of the intervention
* Hearing impairment not improved with hearing aids and/or sound amplification
* Unable to engage with MBCT for physical or practical reasons
* Ongoing Active Psychotherapy

Primary outcomes:
measure: Significant decrease in the PHQ-9 (depression) score between baseline and 8-week follow-up
timeFrame: week 0 to 8 weeks
Secondary outcomes:
measure: Decrease in the GAD-7 score (anxiety) between baseline and 8-week follow-up
timeFrame: week 0 to 8 weeks
Other outcomes:
measure: Decreases in stress markers between baseline (week 0) and 8-week follow-up
timeFrame: week 0 to 8 weeks
measure: Decreases in inflammatory markers between baseline (week 0) and 8-week follow-up
timeFrame: week 0 to 8 weeks
Locations:
city: Montreal
country: Canada
facility: CLSC Benny Farm
state: Quebec
city: Montreal
country: Canada
facility: CLSC Benny Farm
state: Quebec
Study officials:
References: